fundamentally ptd is one of the better bio's. it has large cash reserves, and an exciting albeit long term product development line. funding this they have royalty income until 2012 from memory and increasing sales from suprelon* (spelling?).
i guess the market sees ptd as being a bit boring because the TNF drugs they are working on are so far down the road to market. occasionally they come out with a hot announcement totally out of the blue so its always worth keeping ptd on the watchlist. not too sure what they are doing with the share buyback, havent read anything about that for months, not sure if they stopped............
PTD Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
